Hypothyroidism Clinical Trials
Here are the 4 most popular medical studies for hypothyroidism
Thyroid Hormone Supplementation for Hypothyroidism in Hemodialysis Patients
This trial will study whether levothyroxine, a medication frequently prescribed for chronic kidney disease patients, is effective and safe for this population. The study will investigate whether levothyroxine improves patient-centered and cardiovascular outcomes in dialysis patients, and if thyroid hormone replacement exerts classic metabolic effects in this population.
Thyroid Hormone Replacement
Levothyroxine Supplementation for Heart Failure
The purpose of this study is to determine whether levothyroxine supplementation is beneficial in patients with systolic heart failure and subclinical hypothyroidism on the functional class evaluated with a 6 minute walk test.
Thyroid Hormone Replacement
Levothyroxine +1 More for Hypothyroidism
Our hypothesis is that hypothyroid patients on DTE may have a decrease in symptoms, an improvement of cognitive function, and an increase in sense of well-being/ quality of life equivalently compared with L-T4.
Hypothyroidism Clinical Trials With No Placebo
View 10 hypothyroidism medical studies that do not have a placebo group.
Hormone Replacement Therapy
Hormone Replacement Therapy for Hypothyroidism
“ I would love to have a medication that would help with some better energy levels and all around well being ! Have been taking Leothroyxine for 20 years and the last 10 has not helped much and very hard to lose weight.”
Frequently Asked Questions
Introduction to hypothyroidism
What are the top hospitals conducting hypothyroidism research?
Advancements in the understanding and treatment of hypothyroidism are being made by top hospitals and research centers across the United States. In Chula Vista, California, ProSciento, Inc. is actively conducting a clinical trial focused on this condition, marking their first recorded trial in 2023. Catalina Research Institute, L.L.C., located in Montclair, is also dedicating its efforts to studying hypothyroidism with an ongoing trial that aligns with the latest medical breakthroughs recorded in 2023. Further south in Miami Lakes, Panax Clinical Research, LLC has joined the fight against hypothyroidism as well. Their active trial demonstrates their commitment to exploring new treatment options for this thyroid disorder since embarking on their inaugural study also initiated in 2023.
Meanwhile,Mt.Olympus Medical Research contributes towards similar goals from Sugar Land where it kickstarted Hypothryoid studies from year of 2023 itself; they're currently working upon one such case too.Rainier Clinical Research Center situated at Renton had set off for similar journey back two years earlier than others around2019,and even after securing participation into only single current trials ,they show remarkable dedication through having accomplished previous pair of them.
Although these numbers may seem small compared to other fields of medical research, each active clinical trial represents a significant step forward in our understanding and management of hypothyroidism—a condition characterized by an underactive thyroid gland resulting in various symptoms like fatigue,lack energy,cognitive impairment etc.This collective effort among specialized institutions and researchers guarantees that patients suffering from this common endocrine disorder can look forward to more effective treatments and improved quality of life moving forward
Which are the best cities for hypothyroidism clinical trials?
When it comes to hypothyroidism clinical trials, several cities have emerged as key players in advancing research and treatment options. Atlanta, Georgia, Orange, California, and Bethesda, Maryland each boast 2 active trials focused on studying different interventions such as North Star, Tirosint®-SOL, Levothyroxine Sodium, and more. Additionally, Chula Vista and Montclair in California also contribute with 1 ongoing trial each exploring treatments like XP-8121. These cities serve as important hubs for individuals seeking potential breakthroughs in the management of hypothyroidism through participation in clinical trials.
Which are the top treatments for hypothyroidism being explored in clinical trials?
Clinical trials are shedding light on the top treatments for hypothyroidism, offering hope to those affected by this condition. Taking the lead is levothyroxine, a medication currently being explored in three active trials dedicated to hypothyroidism. Since its first listing in 2006, it has made significant strides with a total of 31 clinical trials aimed at addressing this thyroid disorder. Another promising option emerging from research is North Star, which has one ongoing trial and was introduced as a treatment for hypothyroidism in 2023. Additionally, Tirosint®-SOL and Levothyroxine Sodium have also shown potential with one active trial each and initial listings in 2022 and 2019 respectively. As these investigations progress, new avenues may be uncovered to enhance treatment options for individuals managing hypothyroidism symptoms.
What are the most recent clinical trials for hypothyroidism?
Recent clinical trials for hypothyroidism have brought forth promising advancements in the field. One such trial, XP-8121, is currently in Phase 2 and became available on 4/21/2023. Similarly, the North Star trial has also reached Phase 2 and was made available on 2/28/2023. These studies aim to enhance our understanding of effective treatments for hypothyroidism and improve patient outcomes. Additionally, Tirosint®-SOL, which entered Phase 4 on 1/21/2022, and Levothyroxine from a Phase 2 study conducted starting from10/28/2020 are shedding light on potential therapeutic options. Although Isovue's Phase 4 trial concluded earlier (on3 /26 /2019), its findings remain relevant as they contribute to our knowledge base regarding hypothyroidism management strategies.
What hypothyroidism clinical trials were recently completed?
Recently, several clinical trials investigating treatments for hypothyroidism have been completed. These trials contribute to the ongoing efforts in improving management options for this condition.